Macrophage Activation Syndrome
Information
- Disease name
- Macrophage Activation Syndrome
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03827343 | Active, not recruiting | Retrospective Study of Immunotherapy Related Toxicities and Factors Impacting Outcomes in Children and Adults With Cancer | January 23, 2019 | December 31, 2025 | |
| NCT01966367 | Active, not recruiting | Phase 1/Phase 2 | CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation | March 2013 | February 2030 |
| NCT02780583 | Active, not recruiting | Phase 1 | Treatment of Macrophage Activation Syndrome (MAS) With Anakinra | May 15, 2016 | April 30, 2024 |
| NCT04339712 | Completed | Phase 2 | Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction | April 2, 2020 | January 8, 2021 |
| NCT03311854 | Completed | Phase 2 | A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH) | February 20, 2018 | May 19, 2020 |
| NCT03332225 | Completed | Phase 2 | A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis | December 15, 2017 | December 31, 2019 |
| NCT06405152 | Recruiting | Assessment of Macrophage Activation syndromE in STill's Disease | September 27, 2023 | September 19, 2024 | |
| NCT05001737 | Recruiting | Phase 3 | Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE | December 15, 2021 | September 2025 |
| NCT05611710 | Recruiting | Phase 2 | Anakinra in Dengue With Hyperinflammation ( AnaDen ) | January 2, 2023 | December 31, 2027 |
| NCT06339177 | Recruiting | Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study | June 23, 2024 | April 1, 2031 | |
| NCT05137496 | Unknown status | Phase 3 | Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome | June 1, 2022 | June 1, 2024 |
| NCT03721809 | Unknown status | N/A | Characterization of the Inflammatory Profile of Patients With Macrophage Activation Syndrome Secondary to Bacterial Sepsis | November 2018 | December 2020 |
| NCT02569463 | Unknown status | Phase 1/Phase 2 | Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS） | June 2014 | June 2018 |
| NCT01095146 | Unknown status | New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome | March 2010 | January 2012 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D055501